Showing 3,721 - 3,740 results of 7,147 for search 'significantly ((((lower decrease) OR (nn decrease))) OR (((greater decrease) OR (mean decrease))))', query time: 0.58s Refine Results
  1. 3721
  2. 3722
  3. 3723
  4. 3724

    Chromatin accessibility analysis of perinatal Vps34-deficient Tregs. by Erienne G. Norton (9612079)

    Published 2025
    “…Relative (normalized to average control in each experiment) fold-change comparisons between genotypes in each cell type are shown in bold (<b>A</b>, <b>B</b>). Data are shown as mean ±  s.e.m. (<b>A</b>, <b>B</b>). Two-tailed Student <i>t</i> test (<b>A</b>, <b>B</b>, <b>I</b>), Benjamini–Hochberg test (<b>C</b>), Wilcoxon rank-sum test (<b>G</b>), Fisher’s exact tes<i>t</i> (<b>H</b>), or binomial test (<b>J</b>); NS, not significant. …”
  5. 3725
  6. 3726

    ELISA kit information. by Shuailin Li (11907158)

    Published 2025
    “…<i>PTGFR</i> and <i>JNK</i> mRNA levels, MMP9 and ADH7 protein levels increased significantly in AN-LSCs after 0.313 μg/mL travoprost treatment (p≤0.039), while NF-κB and ADH7 protein levels decreased significantly in LSCs using 0.313 μg/mL travoprost (p=0.039; p<0.001).…”
  7. 3727

    CONSORT diagram. by Bon-Wook Koo (13773694)

    Published 2024
    “…The overall proportion of patients who experienced any adverse events was 57.8% in the GDFT group and 70.1% in the conventional group (P = 0.038), of which the occurrence of pleural effusion was significantly lower in the GDFT group than in the conventional group (9.5% vs. 19.7%; P = 0.024). …”
  8. 3728

    Raw data. by Bon-Wook Koo (13773694)

    Published 2024
    “…The overall proportion of patients who experienced any adverse events was 57.8% in the GDFT group and 70.1% in the conventional group (P = 0.038), of which the occurrence of pleural effusion was significantly lower in the GDFT group than in the conventional group (9.5% vs. 19.7%; P = 0.024). …”
  9. 3729

    Postoperative outcomes. by Bon-Wook Koo (13773694)

    Published 2024
    “…The overall proportion of patients who experienced any adverse events was 57.8% in the GDFT group and 70.1% in the conventional group (P = 0.038), of which the occurrence of pleural effusion was significantly lower in the GDFT group than in the conventional group (9.5% vs. 19.7%; P = 0.024). …”
  10. 3730

    Postoperative complications. by Bon-Wook Koo (13773694)

    Published 2024
    “…The overall proportion of patients who experienced any adverse events was 57.8% in the GDFT group and 70.1% in the conventional group (P = 0.038), of which the occurrence of pleural effusion was significantly lower in the GDFT group than in the conventional group (9.5% vs. 19.7%; P = 0.024). …”
  11. 3731

    Western blot antibody information. by Shuailin Li (11907158)

    Published 2025
    “…<i>PTGFR</i> and <i>JNK</i> mRNA levels, MMP9 and ADH7 protein levels increased significantly in AN-LSCs after 0.313 μg/mL travoprost treatment (p≤0.039), while NF-κB and ADH7 protein levels decreased significantly in LSCs using 0.313 μg/mL travoprost (p=0.039; p<0.001).…”
  12. 3732

    Information on healthy and aniridia subjects. by Shuailin Li (11907158)

    Published 2025
    “…<i>PTGFR</i> and <i>JNK</i> mRNA levels, MMP9 and ADH7 protein levels increased significantly in AN-LSCs after 0.313 μg/mL travoprost treatment (p≤0.039), while NF-κB and ADH7 protein levels decreased significantly in LSCs using 0.313 μg/mL travoprost (p=0.039; p<0.001).…”
  13. 3733

    qPCR primers information. by Shuailin Li (11907158)

    Published 2025
    “…<i>PTGFR</i> and <i>JNK</i> mRNA levels, MMP9 and ADH7 protein levels increased significantly in AN-LSCs after 0.313 μg/mL travoprost treatment (p≤0.039), while NF-κB and ADH7 protein levels decreased significantly in LSCs using 0.313 μg/mL travoprost (p=0.039; p<0.001).…”
  14. 3734
  15. 3735
  16. 3736
  17. 3737
  18. 3738
  19. 3739
  20. 3740